Nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein, screening method and application thereof

By designing and screening highly homologous nucleic acid aptamers, the problem of insufficient affinity and specificity of nucleic acid aptamers for protein phosphatase 1 regulatory subunit 26 was solved, enabling efficient, stable and low-cost in vivo application, suitable for the detection and treatment of PPP1R26 protein.

CN118931908AActive Publication Date: 2024-11-12ZHEJIANG UNIV OF TECH +1

Patent Information

Application Number
CN202410975902.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-12
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

In the existing technology, nucleic acid aptamers have insufficient affinity and specificity for protein phosphatase 1 regulatory subunit 26, low stability, and complex and costly synthesis and labeling processes, which limits their application in organisms.

Method used

Nucleic acid aptamers with at least 60% homology to the nucleotide sequences of SEQ ID NO.1 to SEQ ID NO.2 were designed and screened using SELEX technology. The aptamers were then used to bind to the protein phosphatase 1 regulatory subunit 26 protein, and RNA sequences were used as aptamers. The aptamers were chemically modified to improve binding affinity and stability.

Benefits of technology

It improves the binding ability and detection sensitivity of nucleic acid aptamers to PPP1R26 protein, reduces non-specific binding, lowers production costs, and enhances in vivo stability and safety, making it suitable for precision medicine and scientific research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004954497710000131
    Figure BDA0004954497710000131
  • Figure BDA0004954497710000141
    Figure BDA0004954497710000141
  • Figure BDA0004954497710000181
    Figure BDA0004954497710000181
Patent Text Reader

Abstract

The invention discloses a nucleic acid aptamer binding to protein of a protein phosphatase 1 regulatory subunit 26, a screening method and application of the nucleic acid aptamer. The nucleic acid aptamer has at least 60% of homology with any one of SEQ ID NO.1-SEQ ID NO.2 and a nucleotide sequence binding to the protein of the protein phosphatase 1 regulatory subunit 26, the sequence of the nucleic acid aptamer has at least 60% of homology with at least one of SEQ ID NO.1-SEQ ID NO.2, and the nucleotide sequence of the nucleic acid aptamer has at least 60% of homology with at least one of SEQ ID NO.1-SEQ ID NO.2. And verification proves that the aptamer can accurately identify and be tightly combined with the PPP1R26 protein. The binding force between the aptamer and the PPP1R26 protein is strong, the target protein can be captured with extremely high efficiency, and the detection sensitivity and the drug targeting efficiency can be improved. In addition, the aptamer is stable in chemical property and not prone to being affected by environmental factors to be degraded, so that it is guaranteed that the aptamer can be applied to the complex in-vivo environment of organisms, and the lasting effectiveness of the aptamer in the in-vivo application process is guaranteed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein, a screening method and an application thereof. Background Art

[0002] Protein phosphatase 1 regulatory subunit 26 is a regulatory subunit of protein phosphatase 1, also known as myosin phosphatase targeting subunit 1 (MYPT1). This protein plays an important role in cell signaling and the regulation of muscle contraction.

[0003] Protein phosphatase 1 regulatory subunit 26 can bind to protein phosphatase 1 (PP1) to form a complex and regulate the enzymatic activity of PP1. This complex is mainly involved in the dephosphorylation process of myosin light chain, thereby affecting the regulation of muscle contraction. In addition, protein phosphatase 1 regulatory subunit 26 may also interact with other signaling molecules and participate in a wider range of cell signal transduction processes.

[0004] Upregulation of protein phosphatase 1 regulatory subunit 26 was significantly associated with metastasis and poor survival in patients with hepatocellular carcinoma. Mechanistically, protein phosphatase 1 regulatory subunit 26 binds to Ser37-phosphorylated PKM2 and TGIF2 in the nucleus and blocks TGIF2 binding to the CDH1 promoter to inhibit CDH1 transcription. Protein phosphatase 1 regulatory subunit 26 promotes glycolysis by enhancing PKM2 splicing, while activating EMT by forming a protein phosphatase 1 regulatory subunit 26-PKM2-TGIF2 complex to drive HCC progression. Therefore, targeting protein phosphatase 1 regulatory subunit 26 attenuates HCC progression and provides a potential therapeutic strategy for HCC patients with upregulation of protein phosphatase 1 regulatory subunit 26.

[0005] The main disadvantages faced by existing technologies when screening nucleic acid aptamers for protein phosphatase 1 regulatory subunit 26 (PPP1R26) include: insufficient affinity and specificity of nucleic acid aptamers, resulting in an increased risk of nonspecific binding; low stability of nucleic acid molecules in the body and easy degradation, affecting the sustained effect of their therapeutic applications; and complex and costly synthesis and labeling processes, which limit large-scale production and wide application. Summary of the invention

[0006] In order to overcome at least one of the defects described in the above-mentioned prior art, the present invention provides a nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein, a screening method and its application, which can solve the problems of insufficient affinity and specificity of existing nucleic acid aptamers for PPP1R26, low stability and high cost.

[0007] The technical solution adopted by the present invention to solve the problem is:

[0008] A nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein, wherein the nucleic acid aptamer has a nucleotide sequence that is at least 60% homologous to any one of SEQ ID NO.1 to SEQ ID NO.2 and binds to protein phosphatase 1 regulatory subunit 26 protein.

[0009] By adopting the above scheme, the nucleic acid aptamer sequence has at least 60% homology with at least one of SEQ ID NO.1 to SEQ ID NO.2, and it has been verified that it can accurately identify and tightly bind to the PPP1R26 protein. The nucleic acid aptamer has a strong binding force with the PPP1R26 protein and can capture the target protein with extremely high efficiency, which can improve the detection sensitivity and drug targeting efficiency. In addition, the chemical properties of the aptamer are stable and not easily degraded by environmental factors, so as to ensure that it can be used in complex biological environments, ensuring its lasting effectiveness when used in vivo. In addition, the high homology design ensures that the aptamer has a high selectivity for the PPP1R26 protein, avoiding non-specific binding of non-target proteins, which is extremely critical for the accuracy of precision medicine and scientific research.

[0010] Furthermore, the nucleic acid aptamer has an RNA sequence transcribed from the nucleotide sequence shown in any one of SEQ ID NO.1 to SEQ ID NO.2.

[0011] By adopting the above scheme, RNA sequences are used as aptamers to form high-intensity specific binding with protein phosphatase 1 regulatory subunit 26 (PPP1R26) protein. The high affinity helps to accurately capture the target protein in complex biological samples and improve the sensitivity and accuracy of detection. In addition, RNA aptamers effectively avoid non-specific binding by accurately matching specific regions of the PPP1R26 protein, ensuring that they only react with the target protein in clinical testing and treatment applications, reducing the risk of misdiagnosis and side effects. RNA aptamers can be easily chemically modified with fluorescent markers, radioactive substances, biotin and other labels for easy imaging, tracking and detection. In addition, the flexibility of its structure also allows further modification to make it a drug delivery carrier or coupled with other therapeutic molecules to achieve multifunctional applications.

[0012] Compared with traditional antibodies, RNA aptamers are chemically synthesized based on known sequences and do not rely on cell expression systems, which greatly shortens the R&D cycle, reduces production costs, and can quickly adapt to different needs for sequence optimization and customization. In addition, RNA aptamers do not trigger immune responses, reduce potential side effects during use, and are more suitable for long-term treatment and in vivo applications.

[0013] Furthermore, the nucleic acid aptamer has a nucleotide sequence as shown in any one of SEQ ID NO.1 to SEQ ID NO.2.

[0014] By adopting the above scheme, nucleic acid aptamers form stable and specific complexes through precise complementarity with PPP1R26 protein, showing stronger binding ability than traditional molecules such as antibodies. Compared with proteins (such as antibodies), nucleic acid aptamers have smaller molecular weights, which makes their distribution in the body more uniform and their ability to penetrate cell membranes stronger. At the same time, their chemical properties are stable and not easily metabolized and degraded, which helps to increase the half-life in the body and extend the therapeutic window.

[0015] Moreover, the structure of nucleic acid aptamers is simple, and it is convenient to add fluorescent markers, biotin, radioisotopes or other functional groups during the synthesis process. Without complex protein engineering, the visual tracking or functional enhancement of the target molecule can be achieved, which greatly facilitates research and clinical applications. In addition, as non-protein molecules, nucleic acid aptamers will not trigger the body's immune response, reducing potential side effects, making them safer when used in vivo. The nucleic acid aptamers based on SEQ ID NO.1 to SEQ ID NO.2 can not only be used for high-sensitivity detection, purification and imaging of PPP1R26 protein, but also can be used to develop therapeutic drugs for diseases related to abnormal expression of PPP1R26, such as hepatocellular carcinoma (HCC), providing a new means for disease diagnosis and treatment.

[0016] The present invention also provides a conjugate or derivative of a nucleic acid aptamer, using the nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein, wherein the conjugate of the nucleic acid aptamer includes a fluorescent marker;

[0017] The derivatives of the nucleic acid aptamer include a phosphorothioate backbone or a peptide nucleic acid that binds to the protein phosphatase 1 regulatory subunit 26 protein and is formed by modifying the nucleotide sequence backbone of the nucleic acid aptamer or the conjugate of the nucleic acid aptamer.

[0018] By adopting the above scheme, the present invention not only proposes efficient nucleic acid aptamers for protein phosphatase 1 regulatory subunit 26 (PPP1R26) protein, but also further expands the application potential of these aptamers, and greatly enriches their application range in scientific research and medical fields by creating conjugates and derivatives thereof. Specifically, the conjugates of nucleic acid aptamers provide the possibility of visual tracking and real-time monitoring by adding fluorescent markers. This labeling is not only conducive to directly observing and quantifying the expression and distribution of PPP1R26 protein at the cellular or tissue level, but also provides a powerful tool for living cell imaging, targeted drug delivery, and biological process research.

[0019] In addition, derivatives of nucleic acid aptamers have been endowed with new physical and chemical properties through innovative modifications of chemical structures, such as converting the original nucleotide sequence backbone into a phosphorothioate backbone or peptide nucleic acid. The introduction of the phosphorothioate backbone enhances the stability of the aptamer and its resistance to nucleases, while generally improving its binding affinity to the target protein and prolonging its half-life in the body, thus improving the therapeutic effect. Due to their special non-charged properties, peptide nucleic acid (PNA) derivatives can penetrate cell membranes more effectively and bind more tightly to target proteins, and have great potential in drug delivery and gene regulation.

[0020] The present invention also provides a method for screening nucleic acid aptamers, which specifically comprises the following steps:

[0021] S1. Design of random single-stranded DNA library: Based on the characteristics of protein phosphatase 1 regulatory subunit 26 (PPP1R26), a single-stranded DNA library containing random nucleotide sequence regions was designed. The library design also included specific primer binding regions.

[0022] S2, synthesizing forward and reverse primers matching the library design, as well as primers that may contain markers, for subsequent screening and detection;

[0023] S3, positive screening: using a microplate pretreated with protein phosphatase 1 regulatory subunit 26 for screening, so that only nucleic acid fragments that specifically bind to PPP1R26 are retained;

[0024] Counterscreening: Microplates treated with bovine serum albumin (BSA) or other non-target proteins are used to remove non-specifically bound nucleic acid sequences.

[0025] S4, repeating multiple rounds of positive screening and reverse screening processes, enriching the nucleic acid sequences binding to PPP1R26 by PCR amplification after each round of screening, and gradually increasing the proportion of specific nucleic acid aptamers in the library;

[0026] S5. Use QPCR to monitor the Cq value of elution after each round of screening, as well as the molecular retention rate, to evaluate the screening efficiency;

[0027] S6. Apply SPR technology to directly measure the binding ability of the enriched library with PPP1R26 protein after different screening rounds to obtain specific affinity data.

[0028] S7. Select candidate nucleic acid sequences that show high binding ability after several rounds of screening, and use SPR to further confirm their affinity and specificity with PPP1R26 protein;

[0029] S8. Performing a dot blot hybridization experiment to verify the binding ability of these candidate nucleic acid aptamers to PPP1R26 protein and control protein;

[0030] S9. Analyze the screening results and optimize the screening conditions as needed, such as adjusting the elution conditions, increasing the number of screening rounds, or changing the screening buffer, to further improve the performance of the nucleic acid aptamer.

[0031] By adopting the above scheme, through the strategy of combining positive screening with reverse screening, non-specific binding nucleic acid sequences can be quickly removed, and only the part that specifically binds to the PPP1R26 protein is retained, which greatly improves the screening efficiency. Multiple rounds of cyclic screening and PCR amplification gradually enrich the target nucleic acid aptamers, ensuring that the screened sequences have high specificity and binding ability.

[0032] Using QPCR to monitor the molecular retention rate and Cq value of each round of screening can quantitatively analyze the screening efficiency and adjust the strategy in time. The application of SPR technology directly provides accurate quantitative data on the binding ability of the enriched library with the PPP1R26 protein, including affinity (KD value), ensuring that the selected nucleic acid aptamers have excellent binding performance.

[0033] The specific binding of the candidate aptamer to the PPP1R26 protein was further verified by dot hybridization experiments. At the same time, experimental comparison with the control protein ruled out the possibility of nonspecific binding, ensuring the high specificity of the selected aptamer.

[0034] This screening method allows for adjustment of conditions based on actual screening results, such as elution conditions, screening rounds, or buffer formulations, which can help optimize for different needs and challenges to achieve the best screening results.

[0035] The screened high-affinity and high-specificity nucleic acid aptamers not only provide key components for the development of diagnostic kits for protein phosphatase 1 regulatory subunit 26-related diseases, but also lay the foundation for the innovation of targeted drug design and treatment strategies. They have important scientific significance and clinical application value.

[0036] The present invention also provides an application of the above-mentioned nucleic acid aptamer in the preparation of a protein phosphatase 1 regulatory subunit 26 protein detection, purification or imaging reagent, or an application of a conjugate or derivative of the above-mentioned nucleic acid aptamer in the preparation of a protein phosphatase 1 regulatory subunit 26 protein detection, purification or imaging reagent.

[0037] By adopting the above scheme, nucleic acid aptamers can be used to develop highly sensitive detection methods due to their highly specific and strong binding ability to PPP1R26 protein. The nucleic acid aptamer conjugates combined with fluorescence, radioactivity or enzyme labels can accurately and quickly detect the content of PPP1R26 protein in cells or body fluids through fluorescence imaging, radioactivity measurement or signal changes generated by enzymatic reactions, providing a powerful tool for early diagnosis of diseases.

[0038] In terms of protein purification, nucleic acid aptamers and their conjugates can serve as ligands for affinity chromatography, specifically binding to the target protein PPP1R26, and efficiently separating the protein from complex biological samples. This not only improves the purification efficiency, but also reduces damage to the sample, which is beneficial for subsequent structural analysis and functional research.

[0039] The high specific binding ability of nucleic acid aptamers makes them excellent probes for visualizing the distribution and dynamic changes of PPP1R26 protein at the cellular or tissue level. Whether using fluorescently labeled aptamers for direct imaging or integrating them into more complex imaging systems, they can provide clear spatial resolution, helping researchers to gain a deeper understanding of the mechanism of action of PPP1R26 protein in physiological or pathological processes.

[0040] In addition to basic research, the above aptamers and their derivatives can also be used in drug screening platforms to evaluate the effects of potential drugs on the activity of PPP1R26 protein and accelerate the drug discovery process. In addition, in the field of clinical treatment, by specifically regulating the activity of PPP1R26 protein, nucleic acid aptamers have the potential to become new therapeutic agents for the treatment of related diseases (such as hepatocellular carcinoma).

[0041] The present invention also provides an application of the above-mentioned nucleic acid aptamer in the preparation of a drug targeting protein phosphatase 1 regulatory subunit 26 protein, or an application of a conjugate or derivative of the above-mentioned nucleic acid aptamer in the preparation of a drug targeting protein phosphatase 1 regulatory subunit 26 protein.

[0042] By adopting the above scheme, nucleic acid aptamers can recognize and bind to PPP1R26 protein with high specificity, avoiding the side effects caused by nonspecific binding and improving the accuracy and safety of drug treatment. By directly intervening in the function of PPP1R26 protein, these aptamers and their conjugates or derivatives can effectively regulate related signaling pathways, such as inhibiting the proliferation, migration and invasion of tumor cells, thereby playing a therapeutic role in diseases such as hepatocellular carcinoma (HCC) and improving patient prognosis.

[0043] Compared with traditional drugs, nucleic acid aptamers have a small molecular weight, are non-immunogenic, and can be easily designed into conjugates or derivatives with specific functions. For example, by connecting therapeutic substances, fluorescent markers or specific ligands, they can reduce damage to normal cells while enhancing targeting to lesions, thereby reducing systemic toxic side effects.

[0044] The present invention also provides an application of the above-mentioned nucleic acid aptamer in the preparation of a drug for treating abnormal expression of protein phosphatase 1 regulatory subunit 26 protein, or an application of a conjugate or derivative of the above-mentioned nucleic acid aptamer in the preparation of a drug for treating abnormal expression of protein phosphatase 1 regulatory subunit 26 protein.

[0045] By adopting the above scheme, using highly specific and high-affinity nucleic acid aptamers and their conjugates or derivatives (such as thiophosphate backbones, peptide nucleic acids), innovative therapeutic drugs are developed for the abnormal expression of protein phosphatase 1 regulatory subunit 26 (PPP1R26). These aptamers can effectively regulate its related disease signaling pathways by precisely targeting the PPP1R26 protein, such as inhibiting tumor progression in the treatment of hepatocellular carcinoma, while reducing the impact on normal tissues, and improving the safety and efficacy of treatment. The conjugation or derivative design enhances the in vivo stability and cell penetration of the aptamer, promotes the efficiency of drug delivery, and provides possibilities for personalized medicine and multimodal treatment strategies. In addition, they also have the unique advantage of being a diagnostic tool to monitor treatment responses, which has brought revolutionary progress to the research and treatment of PPP1R26-related diseases, and has shown great clinical application potential and social value.

[0046] The present invention also provides a protein phosphatase 1 regulatory subunit 26 protein detection kit prepared by the above-mentioned nucleic acid aptamer, or a protein phosphatase 1 regulatory subunit 26 protein detection kit prepared by the above-mentioned nucleic acid aptamer conjugate or derivative.

[0047] By adopting the above scheme, the protein detection kit can significantly improve the specificity and sensitivity of the detection. The kit uses the advantages of nucleic acid aptamers and their conjugates or derivatives to achieve rapid and accurate identification of PPP1R26 protein, and can accurately capture even trace samples, providing a simple, efficient and stable tool for disease diagnosis. It is not only suitable for a variety of sample types, broadening the scope of application, but also improves the comfort of patients through non-invasive or minimally invasive detection methods. In addition, the cost-effectiveness and easy large-scale production of nucleic acid aptamers make the kit show broad application potential and significant social value in clinical practice, scientific research and even public health monitoring.

[0048] In summary, the present invention designs and synthesizes a random single-stranded DNA library and corresponding primers based on the SELEX technology, which are used to screen nucleic acid aptamers that have small molecular weight, stable chemical properties, are easy to store and label, and can bind to protein phosphatase 1 regulatory subunit 26 protein with high affinity, thereby screening out some nucleic acid aptamers that bind to protein phosphatase 1 regulatory subunit 26 protein with high affinity, namely XJ01 (SEQ ID NO.1) and XJ02 (SEQ ID NO.2), which have higher affinity and higher specificity to protein phosphatase 1 regulatory subunit 26 protein.

[0049] Due to the particularity of the nucleotide sequence, a certain position on the nucleotide sequence of the above-mentioned nucleic acid aptamer can be modified, for example, phosphorylation, methylation, amination, sulfhydrylation, replacement of oxygen with sulfur, replacement of oxygen with selenium or isotopization, etc., provided that the nucleic acid aptamer sequence obtained after such modification has desirable properties, for example, it can have an affinity for binding to protein phosphatase 1 regulatory subunit 26 protein equal to or higher than that of the parent nucleic acid aptamer sequence before modification, or although the affinity is not significantly improved, it has higher stability. It is understandable that the nucleotide sequence having at least 30%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, at least 98% or at least 99% homology with the nucleic acid aptamer provided by the present invention and binding to protein phosphatase 1 regulatory subunit 26 protein, for example, the nucleotide sequence shown in any one of the above-mentioned nucleic acid aptamers can be deleted or a portion of the sequence can be added, and still have a high affinity for protein phosphatase 1 regulatory subunit 26 protein.

[0050] In other words, the above aptamers, whether partially substituted or modified, have substantially the same or similar molecular structures, physicochemical properties and functions as the original aptamers, and can be used to bind to protein phosphatase 1 regulatory subunit 26 protein.

[0051] In a second aspect, the present invention provides a conjugate or derivative of a nucleic acid aptamer, wherein the nucleic acid aptamer has a nucleotide sequence as shown in any one of SEQ ID NO.1 to SEQ ID NO.2; the conjugate of the nucleic acid aptamer includes a fluorescent marker; the derivative of the nucleic acid aptamer includes a thiophosphate backbone or peptide nucleic acid that binds to the protein phosphatase 1 regulatory subunit 26 protein, which is modified from the nucleotide sequence backbone of the nucleic acid aptamer or the conjugate of the nucleic acid aptamer.

[0052] The conjugate of the nucleic acid aptamer described in the present invention refers to connecting other groups to the nucleic acid aptamer, such as fluorescent markers with marking functions, such as FAM, radioactive substances, therapeutic substances, biotin, digoxin, nanoluminescent materials, small peptides, siRNA or enzyme labels, so that the nucleic acid aptamer sequence obtained after modification has desirable properties, for example, it can have an affinity for binding to protein phosphatase 1 regulatory subunit 26 protein that is equal to or higher than that of the parent nucleic acid aptamer sequence before modification, or although the affinity is not significantly improved, it has higher stability.

[0053] The nucleic acid aptamer derivatives of the present invention are obtained by transforming the nucleotide sequence skeleton of the nucleic acid aptamer into a phosphorothioate skeleton that binds to the protein phosphatase 1 regulatory subunit 26 protein, or are peptide nucleic acids that bind to the protein phosphatase 1 regulatory subunit 26 protein transformed from the nucleic acid aptamer or the conjugate of the nucleic acid aptamer in any of the above technical solutions. The condition is that the derivatives have a molecular structure, physicochemical properties and functions that are substantially the same or similar to those of the original nucleic acid aptamer, and all bind to the protein phosphatase 1 regulatory subunit 26 protein.

[0054] The term "phosphorothioate backbone" as used in the present invention has the meaning generally understood by those of ordinary skill in the art, and refers to that the non-bridging oxygen atoms of the phosphodiester backbone of RNA and DNA aptamers can be replaced by one or two sulfur atoms, resulting in a phosphorothioate backbone with phosphorothioate or phosphorodithioate bonds, respectively. Such phosphorothioate backbones are known to have increased binding affinity to their targets, as well as enhanced resistance to nuclease degradation.

[0055] The term "peptide nucleic acid" used in the present invention has the meaning generally understood by those of ordinary skill in the art, and refers to an artificially synthesized DNA molecule analog, first reported by Nielsen et al. in 1991. Oligonucleotide mimics linked by peptide bonds were synthesized using N-2-(aminoethyl)-glycine units instead of sugar-phosphate backbones as repeating structural units, and are called peptide nucleic acids. Since peptide nucleic acids (PNA) do not have phosphate groups like those on DNA or RNA, there is a lack of electrical repulsion between PNA and DNA, making the binding strength between the two greater than the binding strength between DNA and DNA.

[0056] In a third aspect, the present invention provides a use of the nucleic acid aptamer in the preparation of a protein phosphatase 1 regulatory subunit 26 protein detection, purification or imaging reagent.

[0057] In a fourth aspect, the present invention provides a use of the nucleic acid aptamer in the preparation of a drug targeting protein phosphatase 1 regulatory subunit 26 protein.

[0058] In a fifth aspect, the present invention provides a use of the nucleic acid aptamer in the preparation of a drug for treating abnormal expression of protein phosphatase 1 regulatory subunit 26 protein.

[0059] In a sixth aspect, the present invention provides a protein phosphatase 1 regulatory subunit 26 protein detection product prepared using the nucleic acid aptamer. The product comprises the nucleic acid aptamer, or a conjugate or derivative of the nucleic acid aptamer.

[0060] In addition, the nucleic acid aptamer, its conjugate or its derivative described in the present invention has any of the following uses:

[0061] 1) Quantitative or qualitative detection of protein phosphatase 1 regulatory subunit 26 protein;

[0062] 2) Purify protein phosphatase 1 regulatory subunit 26 protein;

[0063] 3) Imaging of protein phosphatase 1 regulatory subunit 26 protein;

[0064] 4) as an inhibitor of protein phosphatase 1 regulatory subunit 26 protein;

[0065] 5) preparing drugs targeting protein phosphatase 1 regulatory subunit 26 protein;

[0066] 6) Preparing reagents or drugs for diagnosing and treating abnormal expression of protein phosphatase 1 regulatory subunit 26.

[0067] Compared with the prior art, the nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein, the screening method and the application thereof provided by the present invention have the following technical effects:

[0068] 1. By improving the screening conditions, a nucleic acid aptamer with small molecular weight, stable chemical properties, easy storage and labeling was obtained, which can bind to protein phosphatase 1 regulatory subunit 26 protein with high affinity and high specificity;

[0069] 2. The nucleic acid aptamer has a relatively stable and simple structure, is easy to modify, can be artificially synthesized in a short period of time, has stable chemical properties, and is easy to store and label;

[0070] 3. The nucleic acid aptamer obtained by the present invention can be used for detection, purification or imaging of protein phosphatase 1 regulatory subunit 26 protein, and can also be used to prepare drugs for diagnosis or treatment of abnormal expression of protein phosphatase 1 regulatory subunit 26 protein, such as purification to obtain high-sensitivity and high-specificity detection of protein phosphatase 1 regulatory subunit 26 protein; can be used to prepare drugs targeting protein phosphatase 1 regulatory subunit 26 protein; can be used to prepare reagents or drugs for diagnosis or treatment of abnormal expression of protein phosphatase 1 regulatory subunit 26, etc., and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1 The positive and negative screening elution Cq (A) and molecule retention rate (B) obtained by 6 rounds of screening using QPCR (real-time fluorescence quantitative PCR) in Example 1.

[0072] Figure 2 This is a schematic diagram of the binding ability of the enriched library obtained in the 1st, 3rd and 6th rounds of screening with the target protein detected by SPR (surface plasmon resonance) in Example 1.

[0073] Figure 3 This is a graph showing the affinity detection data of nucleic acid aptamer XJ01 and protein phosphatase 1 regulatory subunit 26 protein detected by SPR (surface plasmon resonance) in Example 2.

[0074] Figure 4 This is a data diagram of the affinity detection of nucleic acid aptamer XJ02 and protein phosphatase 1 regulatory subunit 26 protein using SPR (surface plasmon resonance) in Example 2.

[0075] Figure 5 This is the affinity test data diagram of the nucleic acid aptamer XJ01 in Example 3 and the control proteins Fibrinogen protein and holo-Transferrin protein (two names are written on it).

[0076] Figure 6 This is the affinity test data diagram of the nucleic acid aptamer XJ02 in Example 4 and the control proteins Fibrinogen protein and holo-Transferrin protein (two names are written on it).

[0077] Figure 7 This is a schematic diagram of the results of the dot hybridization experiment based on the nucleic acid aptamer XJ01 in Example 3 to detect the protein phosphatase 1 regulatory subunit 26 protein and the control proteins IgG2, Fibrinogen, and holo-Transferrin.

[0078] Figure 8 This is a schematic diagram of the results of the dot hybridization experiment based on the nucleic acid aptamer XJ02 in Example 4 to detect protein phosphatase 1 regulatory subunit 26 protein and control proteins IgG2, Fibrinogen, and holo-Transferrin. DETAILED DESCRIPTION

[0079] For better understanding and implementation, the technical solutions in the embodiments of the present invention will be clearly and completely described and discussed below in conjunction with the accompanying drawings of the present invention. Obviously, what is described here is only a part of the examples of the present invention, not all the examples. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0080] In order to facilitate the understanding of the embodiments of the present invention, the following will be further explained by taking specific embodiments as examples in conjunction with the drawings, and each embodiment does not constitute a limitation on the embodiments of the present invention.

[0081] In the description of the present invention, it should be noted that the terms "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside" and "outside" etc. indicate directions or positional relationships based on the directions or positional relationships shown in the accompanying drawings. They are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific direction, be constructed and operated in a specific direction. Therefore, they cannot be understood as limiting the present invention.

[0082] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0083] The reagents not specifically mentioned in the present examples are all known products and were obtained by purchasing commercial products.

[0084] Example 1: Screening of ssDNA nucleic acid aptamers binding to protein phosphatase 1 regulatory subunit 26 protein

[0085] The method for screening a ssDNA nucleic acid aptamer that binds to protein phosphatase 1 regulatory subunit 26 protein in this embodiment comprises the following steps:

[0086] 1. Synthesize the random single-stranded DNA library and primers shown in the following sequence:

[0087] Based on SELEX technology, a random single-stranded DNA library, Lib10 library, was designed and synthesized:

[0088] 5'-ATTGGCACTCCACGCATAGG(36N)CCTATGCGTGCTACCGTG AA-3'; wherein "36N" represents a sequence formed by connecting 36 arbitrary nucleotide bases. The library was synthesized by Shanghai Biotech Co., Ltd. (hereinafter referred to as "Shanghai Biotech").

[0089] Primer information is shown in Table 1 and was synthesized by Nanjing GenScript Biotechnology Co., Ltd.

[0090] Table 1. Primers and their sequences:

[0091] Primer name Sequence (5'-3') Lib10S1 ATTGGCACTCCACGCATAGG Lib10-FAM-S1 FAM-ATTGGCACTCCACGCATAGG Lib10-Biotin-A2 Biotin-TTCACGGTAGCACGCATAGG Lib10A2 TTCACGGTAGCACGCATAGG

[0092] The S in the primer name represents the forward primer, and the A represents the reverse primer.

[0093] The primers were prepared into 100 μM stock solution with ddH2O and stored at -20°C for future use.

[0094] 2. New microplate screening

[0095] The novel microplate method was used to screen protein phosphatase 1 regulatory subunit 26 protein nucleic acid aptamers, and a total of 6 rounds of screening were performed. The screening process of each round is shown in Table 2.

[0096] Table 2. Screening process of nucleic acid aptamers for protein phosphatase 1 regulatory subunit 26

[0097]

[0098]

[0099] Phosphate buffer: final concentration of disodium hydrogen phosphate is 100 mM, final concentration of sodium dihydrogen phosphate is 100 mM, solvent is water, pH 8.5, stored at 25°C.

[0100] The specific screening process is as follows:

[0101] Plating of protein phosphatase 1 regulatory subunit 26 protein (positive screening plating)

[0102] Take 2μg of protein phosphatase 1 regulatory subunit 26 protein (purchased from Suzhou Younuozhen Biotechnology Co., Ltd., Uniport ID: P03280PA, concentration 1.2mg / mL), add 100μL of phosphate buffer and mix well so that the protein can bind to the plate, which is the diluted protein phosphatase 1 regulatory subunit 26 protein. Add to the new microplate, incubate on a shaker for one hour, and wash three times with DPBS buffer after incubation. Add 300μL 1mg / mL BSA to block the whole well plate at room temperature for 10 minutes. Wash three times with DP BS. Add 200ul of 0.06M EDC and incubate for 10 minutes; after discarding the supernatant, add 200ul1M ethanolamine for blocking for 10 minutes, wash three times for standby use.

[0103] 2) Plating of BSA protein (counter-screening plating) is the same as step 1), except that the protein phosphatase 1 regulatory subunit 26 protein is replaced with 2 μg of protein (at a concentration of 1 mg / ml), and 200 μL of phosphate buffer is added to allow the protein to bind to the plate. The plate is incubated for one hour, and then washed three times with DPBS buffer for later use.

[0104] 3) Library dissolution and denaturation treatment

[0105] Take the Lib10 random single-stranded nucleotide library (1OD) synthesized by Bio-Industry, centrifuge at 12000rpm for 10 minutes, centrifuge the library to the bottom of the tube, dissolve it to 5μM with DPBS buffer, mix it and dispense it into PCR tubes for denaturation treatment. The treatment process is as follows: set the PCR instrument program to 95℃ for 10 minutes. The purpose of this step is to unwind the folded chain, then keep it at 4℃ for 5 minutes, and then balance it to room temperature. Then add Mg2+ (final concentration of 5mM), BSA (final concentration of 0.5mg / mL), and HSDNA (final concentration of 0.05mg / mL) to the library and mix it to provide the ionic environment required for single-stranded DNA, reduce nonspecific binding and increase competitiveness. This is the library after denaturation treatment.

[0106] 4) Reverse screening

[0107] Add 200 μL of the processed library to the well plate with BSA protein and incubate for one hour. After the incubation, collect the supernatant and mark it as Pool-. The supernatant is used as the single-stranded nucleic acid library. Wash the magnetic beads 4 times with 200 μL DPBS buffer in the new microplate. Finally, add 100 μL of ultrapure water to the washed new microplate, boil it in a boiling water bath for 10 minutes, collect the supernatant (i.e., the anti-screening supernatant), and mark it as elution-BSA.

[0108] 5) Positive screening

[0109] The collected supernatant was added to the new microplate with protein phosphatase 1 regulatory subunit 26 protein and incubated for 60 minutes. After the incubation, the supernatant was discarded and the new microplate was washed 4 times with 200 μL DPBS buffer. Finally, 100 μL ultrapure water was added to the washed new microplate, and the supernatant was collected and marked as elution-protein phosphatase 1 regulatory subunit 26.

[0110] 6) Preparation of secondary library

[0111] 10 μL step 5) elution-protein phosphatase 1 regulatory subunit 26 and elution-BSA in the counter-screening process were quantified by QPCR, and the screening process was monitored by calculating the number of molecules retained in each round. The results are shown in Figure 1 .

[0112] The nucleic acid molecule in step 5) elution-protein phosphatase 1 regulatory subunit 26 was used as a template and amplified by ordinary PCR. The method is as follows: 90 μL template elution-protein phosphatase 1 regulatory subunit 26 was added to 900 μL PCR mix and mixed, 10 μL ultrapure water was added, and the template and PCR mix mixture was divided into 100 μL / tube and added to the PCR tube. The amplification conditions are as follows: 95℃ pre-denaturation for 2 minutes, 95℃ denaturation for 30 seconds, 58℃ annealing for 30 seconds, 72℃ extension for 30 seconds, a total of 25 cycles, and stored at 4℃. The PCR raw materials in the PCRmix are prepared by dNTPs (P031-02) purchased from Novozymes and rtaq enzyme (R500Z) purchased from Takara Biotech.

[0113] The amplified product was purified using commercially available Tiandirenhe SA magnetic beads (SM017010) to prepare a secondary library for the next round of screening. Prepare 80 μL SA magnetic beads, wash twice with 500 μL DPBS buffer containing 5 mM Mg2+ and 0.02% Tween20, discard the supernatant by magnetic suction, add 1000 μL of the PCR product from step 6), and then add 1 / 5 volume of 4M sodium chloride aqueous solution of the PCR product, incubate on a shaker at room temperature for 30 minutes, and discard the supernatant by magnetic suction. Wash the magnetic beads three times with DPBS buffer, remove the supernatant, and add 100 μL of 40 mM sodium hydroxide aqueous solution. Incubate at room temperature for three minutes and then remove the magnetic beads by magnetic suction. Then add 4 μL of 1M hydrochloric acid to the supernatant to neutralize the single chain, and then add 104 μL of 2*DPBS buffer to dilute and neutralize the salt concentration, and finally obtain 208 μL of the secondary library dissolved in 1*DPBS buffer, which can be used as the library for the next round of screening.

[0114] The novel microplate method was used to repeat 5 rounds of screening, each operation using the secondary library obtained in the previous operation as the starting nucleic acid library, and the operation was performed according to steps 3), 4), 5) and 6).

[0115] Example 2: Surface Plasmon Resonance (SPR) Detection of Library Affinity

[0116] The library enrichment was determined based on the QPCR Cq value of elution during each round of positive and negative screening. If the number of templates eluted in each round of positive screening increased (Cq advanced) with the increase in screening rounds and the number of templates eluted in the last round was more than 100 times that of the first round, the screening was stopped. Figure 1The retention rate of each round of molecules calculated based on the elution Cq values ​​of the positive and negative screens showed that the retention rate of the positive screen gradually increased, indicating that the library was effectively enriched. 1. The protein phosphatase 1 regulatory subunit 26 protein was coupled to the 8th channel and the 2nd injection hole on the surface of the CM5 chip of the surface plasmon resonance instrument (GE Healthcare, model: Biacore 8K) as the experimental channel. The specific method is as follows: first wash the chip with 50mM NaOH aqueous solution, inject 20μL, and the flow rate is 10μL / min, then mix equal volumes of EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; 0.4M aqueous solution) and NHS (N-hydroxysuccinimide; 0.1M aqueous solution) and inject 105μL to activate the chip, and the flow rate is 10μL / min. The protein phosphatase 1 regulatory subunit 26 protein (purchased from Suzhou Unigene Biotech Co., Ltd., Uniport ID: P03280PA, concentration 1.2 mg / mL) was diluted with 10 mM sodium acetate buffer at pH 5.5 to a final concentration of 50 μg / mL and then injected, the injection volume was 190 μL, the flow rate was 10 μL / min, and the protein phosphatase 1 regulatory subunit 26 protein coupling amount was about 1195.3 Ru. After the injection was completed, the chip was sealed with ethanolamine, the flow rate was 10 μL / min, and 129 μL was injected.

[0117] The operation is the same as that of the second injection hole, except that the protein phosphatase 1 regulatory subunit 26 protein is replaced by the His protein (same as in Example 1), and the other operations are the same. The His protein is coupled to the injection hole channel as a control channel.

[0118] The single-stranded libraries obtained in the first, third and sixth rounds of screening were selected for denaturation treatment: 40 μL of 200 nM single-stranded library was taken and labeled as protein phosphatase 1 regulatory subunit 26 Pool 1, protein phosphatase 1 regulatory subunit 26 Pool 3, and protein phosphatase 1 regulatory subunit 26 Pool 6 respectively.

[0119] Detection: Three rounds of library protein phosphatase 1 regulatory subunit 26 Pool1, protein phosphatase 1 regulatory subunit 26 Pool3, protein phosphatase 1 regulatory subunit 26 Pool6 flow through the second injection hole in sequence. The program for each channel is as follows: library injection 30 μL / min, time 3 minutes; DPBS buffer (containing 5mM Mg2+) injection 30 μL / min for dissociation, time 3 minutes; 2M NaCl aqueous solution injection 30 μL / min for regeneration, time 45 seconds. Results are shown in Figure 2 shown.

[0120] Figure 2Among the samples, protein phosphatase 1 regulatory subunit 26Pool1, protein phosphatase 1 regulatory subunit 26Pool3, and protein phosphatase 1 regulatory subunit 26Pool5, it can be seen that Pool1 has a high affinity because only positive screening and overnight incubation were performed in the first round, and no reverse screening was performed. Protein phosphatase 1 regulatory subunit 26Pool6 is much higher than protein phosphatase 1 regulatory subunit 26Pool1 and protein phosphatase 1 regulatory subunit 26Pool3, meeting the sequencing requirements, and the resulting library was analyzed by high-throughput sequencing.

[0121] Example 3: Surface Plasmon Resonance (SPR) Detection of Affinity between Protein Phosphatase 1 Regulatory Subunit 26 Protein Aptamer and Protein Phosphatase 1 Regulatory Subunit 26 Protein

[0122] Analysis and identification of nucleic acid aptamers obtained after screening: After high-throughput sequencing analysis of the obtained enriched library products, several sequences were selected and synthesized by Genewise Biotechnology (Jiangsu) Technology Co., Ltd., and the affinity was tested.

[0123] In subsequent testing, two sequences with strong binding ability were identified from the sequences obtained in the final sixth round.

[0124] Table 3, SEQ ID No1 and SEQ ID No2 sequence listing:

[0125]

[0126] Suzhou Genewise Biotechnology Co., Ltd. was commissioned to synthesize nucleic acid aptamers XJ01 and XJ02, which were diluted with DPBS buffer (containing 5 mM Mg2+) to 500 nM, 250 nM, 125 nM, 62.5 nM, and 31.25 nM, respectively.

[0127] 1. The protein phosphatase 1 regulatory subunit 26 protein was coupled to the 8th channel and the 2nd injection hole on the surface of the CM5 chip of a surface plasmon resonance instrument (GE Healthcare, model: Biacore 8K) as the experimental channel. The specific method was as follows: first, the chip was cleaned with a 50 mM NaOH aqueous solution, 20 μL was injected, and the flow rate was 10 μL / min. Then, equal volumes of EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; 0.4 M aqueous solution) and NHS (N-hydroxysuccinimide; 0.1 M aqueous solution) were mixed and 105 μL was injected to activate the chip at a flow rate of 10 μL / min. The protein phosphatase 1 regulatory subunit 26 protein (purchased from Suzhou Younuozhen Biotechnology Co., Ltd., Uniport ID: P03280PA, concentration of 1.2 mg / mL) was diluted with 10mM sodium acetate buffer at pH 5.5 to a final concentration of 50μg / mL and then injected, the injection volume was 190μL, the flow rate was 10μL / min, and the protein phosphatase 1 regulatory subunit 26 protein coupling amount was about 1195.3Ru. After the injection was completed, the chip was sealed with ethanolamine, the flow rate was 10μL / min, and 129μL was injected.

[0128] The same operation as the second injection hole was performed, except that the protein phosphatase 1 regulatory subunit 26 protein was replaced with the His protein (same as in Example 1), and the other operations were the same, and the His protein was coupled to the first injection hole channel as a control channel.

[0129] 2. Detection: The diluted nucleic acid aptamer XJ1 sample flows through the second injection hole in turn. The procedure of each channel is as follows: nucleic acid aptamer injection 30μL / min, time 3 minutes; DPBS buffer (containing 5mM Mg2+) injection 30μL / min for dissociation, time 3 minutes; 2M NaCl aqueous solution injection 30μL / min for regeneration, time 45 seconds. Results are shown in Figure 3 shown.

[0130] Under the same conditions, the aptamer XJ01 sample was replaced with the aptamer XJ2, and other operations were the same. The results are shown in Figure 4 shown.

[0131] The affinity KD values ​​of protein phosphatase 1 regulatory subunit 26 protein aptamers XJ01 and XJ02 with protein phosphatase 1 regulatory subunit 26 protein are shown in Table 4.

[0132] Table 4. Affinity of nucleic acid aptamers to protein phosphatase 1 regulatory subunit 26 protein

[0133] Aptamers length Affinity KD (nM) XJ01 76 1.87 XJ02 76 22.7

[0134] As can be seen from Table 4, the affinity of XJ01 and XJ02 provided by the present invention to protein phosphatase 1 regulatory subunit 26 protein is obviously very high (the smaller the KD value, the greater the affinity).

[0135] Table 4 Figure 3 , Figure 4 These data indicate that these nucleic acid aptamers were detected to have strong binding with protein phosphatase 1 regulatory subunit 26 protein using SPR instrument.

[0136] Example 4: Study on the specificity of nucleic acid aptamers

[0137] Fibrinogen protein (Cat. No.: SLCQ2911, purchased from Merck), holo-Transferrin protein (Cat. No.: SLCQ3428, purchased from Merck).

[0138] In this embodiment, Fibrinogen protein and holo-Transferrin protein are used to replace protein phosphatase 1 regulatory subunit 26 protein, respectively. The method of fixing protein phosphatase 1 regulatory subunit 26 protein to the SPR chip for testing is the same as in Example 2. Fibrinogen protein and holo-Transferrin protein are coupled to the 5th and 6th channels of the CM5 chip surface, respectively, and the coupling amounts are 7758.9RU and 10976.4RU, respectively. Two nucleic acid aptamers, XJ01 and XJ02, diluted to 500nM, are injected in sequence.

[0139] The affinity test data of nucleic acid aptamer XJ01 and Fibrinogen protein and holo-Transferrin protein are shown in Figure 7 ; The affinity test data of nucleic acid aptamer XJ02 and the above five proteins are shown in Figure 8 ; As can be seen from the figure, nucleic acid aptamers XJ01 and XJ02 cannot bind to these two proteins. It can be seen that the nucleic acid aptamer of protein phosphatase 1 regulatory subunit 26 obtained after screening and optimization has very high specificity in binding to the target.

[0140] Example 5: Detection of protein phosphatase 1 regulatory subunit 26 protein by dot blot hybridization assay based on nucleic acid aptamers

[0141] Suzhou Genewiz Biotech Co., Ltd. was commissioned to synthesize biotin-modified nucleic acid aptamers XJ01 and XJ02.

[0142] Fibrinogen protein (catalog number: SLCQ2911, purchased from Merck), holo-transferrin protein (catalog number: SLCQ3428, purchased from Merck), IgG protein (catalog number: SLCN8818, purchased from Merck).

[0143] Dot hybridization experiments were performed on biotin-modified aptamers XJ01 and XJ02, respectively, and the steps were as follows:

[0144] 1. Specificity of aptamers XJ01 and XJ02 for detecting protein phosphatase 1 regulatory subunit 26 protein by dot blot hybridization assay

[0145] (1) Dissolve protein phosphatase 1 regulatory subunit 26 protein in DPBS buffer to 0.500 mg / mL as the test sample; dissolve control proteins IgG2, Fibrinogen, and holo-Transferrin in DPBS buffer to 0.500 mg / mL as the control sample. Take an 8 cm × 2 cm test strip (nitrocellulose membrane, 0.2 μm, GE Amersham, catalog number 10600001), spot 4 μL of the test sample and control sample on the nitrocellulose membrane, and air dry for 40 minutes.

[0146] (2) Then place the test strip in a 50 mL centrifuge tube, add 6 mL of DPBS buffer containing 10% BSA to soak it, and block it on a shaker at room temperature for 1 hour. After blocking, wash it with DPBS (containing 5 mM Mg2+ and 0.02% Tween20) for 5 minutes, repeat the washing three times, and then aspirate it clean.

[0147] (3) The test strip was transferred to a new 50 mL centrifuge tube, and 500 nM biotin-modified aptamer XJ01 dissolved in 6 mL of DPBS buffer (containing 5 mM Mg2+) was added to soak the test strip. The test strip was incubated on a shaker at room temperature for 30 min. After the incubation, the test strip was washed with DPBS (containing 5 mM Mg2+ and 0.02% Tween20) for 2 min. The washing was repeated 3 times and then aspirated clean.

[0148] (4) Transfer the test strip to a new 50 mL centrifuge tube, add 6 mL of HRP-Streptavidin (purchased from Beyotime Biotech, 1 mg / ml): DPBS buffer = 1:2000 dilution to soak it, and incubate it on a shaker at room temperature for 30 min. After incubation, wash it with DPBS (containing 5 mM Mg2+, 0.02% Tween20) for 2 min, repeat the washing 3 times, and aspirate it clean.

[0149] (5) Transfer the test strip to a clean PE glove, take an ECL color development kit (purchased from Beyond Biotech), mix 100 μL of solution A and 100 μL of solution B, soak the surface of the test strip, and incubate in the dark for 5 min.

[0150] (6) Imaging system observation and photography: ImageQuant from GE Healthcare Life Sciences TM LAS 4000 digital imaging system takes pictures, the results are shown in Figure 7 .

[0151] Under the same conditions, 500 nM biotin-modified aptamer XJ01 was replaced with 500 nM biotin-modified aptamer XJ02. Figure 8 .

[0152] Depend on Figure 7 and Figure 8 It can be seen that compared with the spots of the control proteins IgG2, Fibrinogen, and holo-Transferrin, the protein phosphatase 1 regulatory subunit 26 protein is obvious. This shows that the biotin-modified nucleic acid aptamers XJ01 and XJ02 can be used for the detection of membrane hybrid protein phosphatase 1 regulatory subunit 26 protein, and the control proteins IgG2, Fibrinogen, and holo-Transferrin are almost colorless, which further proves that XJ01 and XJ02 can specifically bind to the protein phosphatase 1 regulatory subunit 26 protein.

[0153] The technical means disclosed in the scheme of the present invention are not limited to the technical means disclosed in the above-mentioned implementation mode, but also include technical schemes composed of any combination of the above-mentioned technical features. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications are also regarded as the protection scope of the present invention.

Claims

1. A nucleic acid aptamer that binds to protein phosphatase 1 regulatory subunit 26 protein, characterized in that: The nucleic acid aptamer has a nucleotide sequence that is at least 60% homologous to any one of SEQ ID NO.1 to SEQ ID NO.2 and binds to the protein phosphatase 1 regulatory subunit 26 protein.

2. The nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein according to claim 1, characterized in that: The nucleic acid aptamer has an RNA sequence transcribed from the nucleotide sequence shown in any one of SEQ ID NO.1 to SEQ ID NO.

2.

3. A nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein according to claim 2, characterized in that: The nucleic acid aptamer has a nucleotide sequence as shown in any one of SEQ ID NO.1 to SEQ ID NO.

2.

4. A conjugate or derivative of a nucleic acid aptamer, characterized in that: A nucleic acid aptamer binding to protein phosphatase 1 regulatory subunit 26 protein according to any one of claims 1 to 3, wherein the conjugate of the nucleic acid aptamer comprises a fluorescent marker; The derivatives of the nucleic acid aptamer include a phosphorothioate backbone or a peptide nucleic acid that binds to the protein phosphatase 1 regulatory subunit 26 protein and is formed by modifying the nucleotide sequence backbone of the nucleic acid aptamer or the conjugate of the nucleic acid aptamer.

5. A method for screening nucleic acid aptamers, characterized in that: The specific steps include: S1. Design of random single-stranded DNA library: Based on the characteristics of protein phosphatase 1 regulatory subunit 26 (PPP1R26), a single-stranded DNA library containing random nucleotide sequence regions was designed. The library design also included specific primer binding regions. S2, synthesizing forward and reverse primers matching the library design, as well as primers that may contain markers, for subsequent screening and detection; S3, positive screening: using a microplate pretreated with protein phosphatase 1 regulatory subunit 26 for screening, so that only nucleic acid fragments that specifically bind to PPP1R26 are retained; Counterscreening: Microplates treated with bovine serum albumin (BSA) or other non-target proteins are used to remove non-specifically bound nucleic acid sequences. S4, repeating multiple rounds of positive screening and reverse screening processes, enriching the nucleic acid sequences binding to PPP1R26 by PCR amplification after each round of screening, and gradually increasing the proportion of specific nucleic acid aptamers in the library; S5. Use QPCR to monitor the Cq value of elution after each round of screening, as well as the molecular retention rate, to evaluate the screening efficiency; S6. Apply SPR technology to directly measure the binding ability of the enriched library with PPP1R26 protein after different screening rounds to obtain specific affinity data. S7. Select candidate nucleic acid sequences that show high binding ability after several rounds of screening, and use SPR to further confirm their affinity and specificity with PPP1R26 protein; S8. Performing a dot blot hybridization experiment to verify the binding ability of these candidate nucleic acid aptamers to PPP1R26 protein and control protein; S9. Analyze the screening results and optimize the screening conditions as needed, such as adjusting the elution conditions, increasing the number of screening rounds, or changing the screening buffer, to further improve the performance of the nucleic acid aptamer.

6. Use of the nucleic acid aptamer according to any one of claims 1 to 3 in the preparation of a protein phosphatase 1 regulatory subunit 26 protein detection, purification or imaging reagent, or use of the conjugate or derivative of the nucleic acid aptamer according to claim 4 in the preparation of a protein phosphatase 1 regulatory subunit 26 protein detection, purification or imaging reagent.

7. Use of the nucleic acid aptamer according to any one of claims 1 to 3 in the preparation of a drug targeting protein phosphatase 1 regulatory subunit 26 protein, or use of the conjugate or derivative of the nucleic acid aptamer according to claim 4 in the preparation of a drug targeting protein phosphatase 1 regulatory subunit 26 protein.

8. Use of the nucleic acid aptamer according to any one of claims 1 to 3 in the preparation of a drug for treating abnormal expression of protein phosphatase 1 regulatory subunit 26 protein, or use of the conjugate or derivative of the nucleic acid aptamer according to claim 4 in the preparation of a drug for treating abnormal expression of protein phosphatase 1 regulatory subunit 26 protein.

9. A protein phosphatase 1 regulatory subunit 26 protein detection kit prepared by the nucleic acid aptamer according to any one of claims 1 to 3, or a protein phosphatase 1 regulatory subunit 26 protein detection kit prepared by the conjugate or derivative of the nucleic acid aptamer according to claim 4.

Citation Information

Patent Citations

  • Design and synthesis method of nucleic acid coding probes for high-throughput sequencing

    CN113736777A

  • Method for high-throughput screening of nucleic acid aptamers

    CN118291442A

  • Sequencing-based proteomics

    US20210147831A1

Cited By

  • Nucleic acid aptamer targeting RUNX1 protein and application

    CN121874198A